Market Summary
USD162.16-0.75
Delayedas of 21 Sep 2023, 12:04 pm-0.46%
JNJ Stock Price
JNJ RSI Chart
JNJ Valuation
JNJ Price/Sales (Trailing)
JNJ Profitability
JNJ Fundamentals
JNJ Revenue
JNJ Earnings
Price Action
52 Week Range
150.71179.75
(Low)(High)
Last 7 days
-0.7%
Last 30 days
-2.6%
Last 90 days
-1.6%
Trailing 12 Months
0.1%
JNJ Financial Health
JNJ Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for JNJ
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-23 | McEvoy Ashley | back to issuer | - | - | -2,787 | evp, ww chair, medtech |
2023-08-23 | Duato Joaquin | back to issuer | - | - | -11,035 | ceo and chairman of the board |
2023-08-23 | Fasolo Peter | back to issuer | - | - | -232 | exec vp, chief hr officer |
2023-08-23 | Wolk Joseph J | back to issuer | - | - | -67.00 | exec vp, cfo |
2023-08-23 | Hait William | back to issuer | - | - | -696 | see remarks |
2023-07-26 | Hait William | acquired | 1,329,290 | 90.44 | 14,698 | see remarks |
2023-07-26 | Hait William | sold | -2,528,060 | 172 | -14,698 | see remarks |
2023-07-25 | Fasolo Peter | sold | -3,406,500 | 170 | -20,000 | exec vp, chief hr officer |
2023-06-12 | Wengel Kathryn E | sold | -1,994,400 | 160 | -12,465 | evp, chief to and risk officer |
2023-05-24 | Wolk Joseph J | gifted | - | - | -55.00 | exec vp, cfo |
Which funds bought or sold JNJ recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-19 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -8.06 | -127,783 | 6,893,340 | 2.89% |
2023-09-18 | CAPE ANN SAVINGS BANK | reduced | -0.34 | 211,425 | 3,502,130 | 2.33% |
2023-09-18 | WASHINGTON CAPITAL MANAGEMENT, INC | reduced | -3.42 | 7,083 | 233,383 | 0.20% |
2023-09-15 | CJM Wealth Advisers, Ltd. | added | 0.06 | 38,552 | 601,992 | 0.31% |
2023-09-14 | Proquility Private Wealth Partners, LLC | added | 2.11 | 246,508 | 2,971,830 | 1.16% |
2023-09-14 | IMS Capital Management | added | 1.23 | 162,886 | 2,172,620 | 1.21% |
2023-09-13 | CGC Financial Services, LLC | new | - | 409,993 | 409,993 | 0.27% |
2023-09-13 | AWM CAPITAL, LLC | reduced | -1.7 | 21,379 | 450,062 | 0.11% |
2023-09-12 | DCM Advisors, LLC | unchanged | - | 33,464 | 526,519 | 0.23% |
2023-09-12 | Prosperity Financial Group, Inc. | reduced | -11.1 | -34,103 | 638,907 | 0.56% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Johnson & Johnson
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.44% | 246,826,621 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.6% | 198,802,769 | SC 13G/A | |
| Feb 14, 2022 | state street corp | 5.51% | 144,996,127 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 8.92% | 234,782,632 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.6% | 200,021,352 | SC 13G/A | |
| Feb 12, 2021 | state street corp | 5.47% | 144,029,634 | SC 13G | |
| Feb 10, 2021 | vanguard group inc | 8.66% | 227,946,104 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.2% | 188,510,542 | SC 13G/A | |
| Feb 13, 2020 | state street corp | 5.77% | 151,867,233 | SC 13G | |
| Feb 12, 2020 | vanguard group inc | 8.67% | 228,297,775 | SC 13G/A |
Recent SEC filings of Johnson & Johnson
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 11, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 8-K | Current Report | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 8-K | Current Report | |
| Aug 23, 2023 | 425 | Prospectus Filed |
JNJ Fair Value
Loading...
Peers (Alternatives to Johnson & Johnson)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 512.5B | 29.5B | 3.56% | 89.32% | 78.88 | 17.36 | 1.53% | 14.16% |
JNJ | 423.3B | 97.8B | -2.65% | 0.10% | 32.43 | 4.33 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -2.13% | 26.48% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 189.8B | 77.9B | -9.16% | -24.26% | 8.84 | 2.44 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.06% | -15.06% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.75% | 544.26% | -74.04 | 4.1K | -86.94% | 71.24% |
PRGO | 4.5B | 4.6B | -11.49% | -16.32% | -66.69 | 0.98 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -11.88% | -19.94% | 34.62 | 2.37 | 0.62% | -24.59% |
INVA | 832.3M | 244.3M | -4.13% | 4.68% | 4.22 | 3.41 | -39.50% | -4.99% |
CRON | 830.8M | 109.5M | 21.79% | -27.57% | -5.79 | 7.59 | -2.66% | -32.13% |
CGC | 480.0M | 453.3M | 110.37% | -71.69% | -0.39 | 1.06 | -16.04% | 55.90% |
ACRS | 479.1M | 31.2M | -7.77% | -52.62% | -4.55 | 15.37 | 407.54% | -26.47% |
OCUL | 269.4M | 54.6M | -13.04% | -44.44% | -2.97 | 4.93 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Johnson & Johnson News
Returns for JNJ
Cumulative Returns on JNJ
8.9%
10-Year Cumulative Returns
7.2%
7-Year Cumulative Returns
5.1%
5-Year Cumulative Returns
5.2%
3-Year Cumulative Returns
Risks for JNJ
What is the probability of a big loss on JNJ?
17.7%
Probability that Johnson & Johnson stock will be more than 20% underwater in next one year
0%
Probability that Johnson & Johnson stock will be more than 30% underwater in next one year.
0%
Probability that Johnson & Johnson stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does JNJ drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Johnson & Johnson was unfortunately bought at previous high price.
Drawdowns
Financials for Johnson & Johnson
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 1.6% | 97,773 | 96,263 | 94,943 | 96,041 | 95,588 | 94,880 | 93,775 | 91,446 | 89,190 | 84,214 | 82,584 | 80,856 | 80,503 | 82,729 | 82,059 | 81,706 | 81,325 | 81,593 | 81,581 | 81,382 | 80,684 |
| Gross Profit | 1.9% | 65,594 | 64,377 | 63,854 | 64,762 | 64,866 | 64,490 | 63,920 | 61,732 | 59,754 | 55,786 | 54,157 | 53,109 | 52,861 | 54,726 | 54,503 | 54,323 | 54,220 | 54,501 | 54,490 | 53,993 | 52,959 |
| S&GA Expenses | 1.8% | 25,404 | 24,965 | 24,765 | 25,407 | 25,318 | 25,165 | 24,659 | 23,962 | 23,393 | 22,313 | 22,084 | 21,666 | 21,609 | 22,162 | 22,178 | 22,130 | 22,299 | 22,496 | 22,540 | 22,594 | 22,474 |
| EBITDA | -100.0% | - | 22,688 | 28,971 | 29,560 | 27,685 | 28,604 | 30,349 | 27,284 | 27,864 | 25,034 | 23,929 | 26,374 | 23,533 | 26,651 | 24,655 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.24* | 0.31* | 0.31* | 0.29* | 0.30* | 0.32* | 0.30* | 0.31* | 0.30* | 0.29* | 0.33* | 0.29* | 0.32* | 0.30* | - | - | - | - | - | - |
| Interest Expenses | 64.0% | 789 | 481 | 276 | 159 | 128 | 130 | 183 | 210 | 234 | 239 | 201 | 199 | 203 | 241 | 318 | 483 | 678 | 848 | 1,005 | 1,029 | 1,015 |
| Earnings Before Taxes | 6.1% | 16,048 | 15,126 | 21,725 | 22,360 | 20,387 | 21,209 | 22,776 | 19,587 | 20,139 | 17,417 | 16,497 | 19,068 | 16,314 | 19,415 | 17,328 | 16,232 | 19,008 | 16,940 | 17,999 | 17,437 | 17,804 |
| EBT Margin | -100.0% | - | 0.16* | 0.23* | 0.23* | 0.21* | 0.22* | 0.24* | 0.21* | 0.23* | 0.21* | 0.20* | 0.24* | 0.20* | 0.23* | 0.21* | - | - | - | - | - | - |
| Net Income | 2.6% | 13,054 | 12,724 | 17,941 | 19,157 | 18,366 | 19,830 | 20,878 | 17,880 | 17,767 | 15,115 | 14,714 | 16,986 | 15,185 | 17,166 | 15,119 | 14,151 | 16,332 | 14,679 | 15,297 | 1,542 | 1,372 |
| Net Income Margin | -100.0% | - | 0.13* | 0.19* | 0.20* | 0.19* | 0.21* | 0.22* | 0.20* | 0.20* | 0.18* | 0.18* | 0.21* | 0.19* | 0.21* | 0.18* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 16,207 | 17,185 | 17,739 | 19,950 | 19,733 | 19,758 | 22,461 | 22,564 | 20,853 | 20,189 | 18,307 | 17,443 | 19,764 | 19,918 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -2.2% | 191,686 | 195,969 | 187,378 | 175,124 | 177,724 | 178,355 | 182,018 | 179,228 | 176,440 | 172,557 | 174,894 | 170,693 | 158,380 | 155,017 | 157,728 | 155,521 | 155,117 | 150,027 | 152,954 | 155,703 | 155,365 |
| Current Assets | -5.9% | 60,567 | 64,388 | 55,294 | 65,236 | 63,847 | 60,424 | 60,979 | 59,889 | 53,769 | 52,533 | 51,237 | 57,578 | 45,892 | 44,226 | 45,274 | 44,333 | 41,799 | 41,987 | 46,033 | 47,194 | 45,438 |
| Cash Equivalents | 10.5% | 21,183 | 19,170 | 14,127 | 11,355 | 10,983 | 10,463 | 14,487 | 17,604 | 14,332 | 12,671 | 13,985 | 18,965 | 11,174 | 15,530 | 17,305 | 16,249 | 14,376 | 14,734 | 18,107 | 16,056 | 17,569 |
| Inventory | 0.6% | 12,888 | 12,809 | 12,483 | 11,675 | 11,437 | 10,990 | 10,387 | 10,387 | 10,100 | 9,952 | 9,344 | 9,599 | 9,424 | 8,868 | 9,020 | 9,173 | 9,263 | 9,086 | 8,599 | 8,678 | 8,810 |
| Net PPE | 2.0% | 20,576 | 20,174 | 19,803 | 18,152 | 18,354 | 18,701 | 18,962 | 18,478 | 18,632 | 18,367 | 18,766 | 17,855 | 17,598 | 17,401 | 17,658 | 17,048 | 17,248 | 17,000 | 17,035 | 16,629 | 16,632 |
| Goodwill | -0.3% | 45,440 | 45,575 | 45,231 | 33,383 | 34,166 | 34,935 | 35,246 | 35,569 | 35,819 | 200 | 36,393 | 1,200 | 33,890 | 1,200 | 33,639 | 33,291 | 33,661 | 2,000 | 30,453 | 30,702 | 6,161 |
| Liabilities | -7.9% | 115,277 | 125,100 | 110,574 | 100,525 | 101,367 | 103,646 | 107,995 | 108,956 | 106,860 | 106,723 | 111,616 | 106,220 | 95,402 | 93,723 | 98,257 | 97,311 | 94,332 | 91,072 | 93,202 | 91,077 | 92,476 |
| Current Liabilities | -10.3% | 54,170 | 60,373 | 55,802 | 45,543 | 44,821 | 43,390 | 45,226 | 44,561 | 38,721 | 40,932 | 42,493 | 38,847 | 36,772 | 33,689 | 35,964 | 35,162 | 31,353 | 29,111 | 31,230 | 27,437 | 27,488 |
| Short Term Borrowings | -34.9% | 11,701 | 17,979 | 12,771 | 4,424 | 4,305 | 4,297 | 3,766 | 3,798 | 3,173 | 3,350 | 2,631 | 5,078 | 5,332 | 2,190 | 1,202 | 2,299 | 1,719 | 1,708 | 2,796 | 1,773 | 2,678 |
| LT Debt, Non Current | -2.9% | 33,901 | 34,928 | 26,888 | 27,603 | 28,292 | 28,851 | 29,985 | 30,130 | 30,310 | 30,263 | 32,635 | 32,680 | 25,062 | 25,393 | 26,494 | 26,919 | 27,699 | 27,660 | 27,684 | 29,480 | 29,405 |
| Shareholder's Equity | 6.0% | 75,149 | 70,869 | 76,804 | 74,599 | 76,357 | 74,709 | 74,023 | 70,272 | 69,580 | 65,834 | 63,278 | 64,473 | 62,978 | 61,294 | 59,471 | 58,210 | 60,785 | 58,955 | 59,752 | 64,626 | 62,889 |
| Retained Earnings | 3.9% | 129,381 | 124,558 | 128,345 | 127,917 | 126,216 | 124,380 | 123,060 | 121,092 | 120,154 | 116,508 | 113,890 | 114,831 | 113,898 | 112,901 | 110,659 | 109,242 | 109,809 | 106,650 | 106,216 | 107,617 | 106,123 |
| Accumulated Depreciation | 1.5% | 30,642 | 30,193 | 29,450 | 28,529 | 28,790 | 29,001 | 28,717 | 28,869 | 28,569 | 28,063 | 28,038 | 27,307 | 26,458 | 25,846 | 25,674 | 25,577 | 25,657 | 25,262 | 24,816 | 24,891 | 24,661 |
| Shares Outstanding | -0.3% | 2,598 | 2,606 | - | 2,628 | 2,630 | 2,629 | - | 2,633 | 2,633 | 2,632 | - | 2,633 | 2,633 | 2,634 | - | 2,635 | 2,653 | 2,661 | - | 2,683 | 2,682 |
| Minority Interest | - | 1,260 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -6.8% | 19,073 | 20,472 | 21,194 | 21,576 | 23,582 | 23,315 | 23,410 | 26,021 | 26,114 | 24,252 | 23,536 | 21,591 | 20,735 | 23,231 | 23,416 | 23,262 | 22,007 | 22,138 | 22,201 | 22,062 | 22,056 |
| Share Based Compensation | 1.4% | 1,182 | 1,166 | 1,138 | 1,140 | 1,118 | 1,106 | 1,135 | 1,080 | 1,077 | 1,049 | 1,005 | 1,005 | 994 | 982 | 977 | 973 | 970 | 968 | 978 | 1,026 | 1,020 |
| Cashflow From Investing | -21.0% | -6,559 | -5,422 | -12,371 | -13,334 | -14,352 | -12,132 | -8,683 | -11,226 | -13,326 | -20,429 | -20,825 | -14,266 | -11,092 | -5,358 | -6,194 | -2,622 | -5,246 | -3,659 | -3,167 | -5,900 | -2,811 |
| Cashflow From Financing | -225.8% | -2,078 | 1,652 | -8,871 | -14,007 | -12,289 | -13,307 | -14,047 | -16,255 | -9,852 | -6,930 | -6,120 | -4,548 | -12,637 | -16,814 | -18,015 | -20,332 | -19,916 | -18,056 | -18,510 | -15,658 | -14,250 |
| Buy Backs | -7.4% | 7,403 | 7,995 | 6,035 | 5,711 | 3,937 | 3,595 | 3,456 | 2,781 | 2,873 | 2,948 | 3,221 | 3,326 | 4,471 | 6,251 | 6,746 | 10,128 | 8,971 | 6,630 | 5,868 | 2,875 | 2,715 |
JNJ Income Statement
2023-07-02Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jul. 02, 2023 | Jul. 03, 2022 | Jul. 02, 2023 | Jul. 03, 2022 | |||||||
| Income Statement [Abstract] | ||||||||||
| Sales to customers | $ 25,530 | $ 24,020 | $ 50,276 | $ 47,446 | ||||||
| Sales to customers percent to sales | 100.00% | 100.00% | 100.00% | 100.00% | ||||||
| Cost of products sold | $ 8,212 | $ 7,919 | $ 16,607 | $ 15,517 | ||||||
| Cost of products sold percent to sales | 32.20% | 33.00% | 33.00% | 32.70% | ||||||
| Gross profit | $ 17,318 | $ 16,101 | $ 33,669 | $ 31,929 | ||||||
| Gross Profit Percent To Sales | 67.80% | 67.00% | 67.00% | 67.30% | ||||||
| Selling, marketing and administrative expenses | $ 6,665 | $ 6,226 | $ 12,803 | $ 12,164 | ||||||
| Selling marketing and administrative expenses percent to sales | 26.10% | 25.90% | 25.50% | 25.60% | ||||||
| Research and development expense | $ 3,829 | $ 3,703 | $ 7,392 | $ 7,165 | ||||||
| Research and development expense percent to sales | 15.00% | 15.40% | 14.70% | 15.10% | ||||||
| In-process research and development impairments | $ 49 | $ 610 | ||||||||
| In-process research and development percent to sales | 0.10% | 1.30% | ||||||||
| Interest income | $ (369) | $ (64) | $ (604) | $ (86) | ||||||
| Interest income percent to sales | (1.50%) | (0.30%) | (1.20%) | (0.20%) | ||||||
| Interest expense, net of portion capitalized | $ 346 | $ 38 | $ 561 | $ 48 | ||||||
| Interest expense, net of portion capitalized percent to sales | 1.40% | 0.20% | 1.10% | 0.10% | ||||||
| Other (income) expense, net* | $ (60) | [1] | $ 273 | $ 7,168 | [2] | $ 171 | ||||
| Other (income) expense, net percent to sales | (0.20%) | 1.10% | 14.30% | 0.40% | ||||||
| Restructuring | $ 145 | $ 85 | $ 275 | $ 155 | ||||||
| Restructuring charge percent to sales | 0.50% | 0.40% | 0.50% | 0.30% | ||||||
| Earnings before provision for taxes on income | $ 6,762 | $ 5,840 | $ 6,025 | $ 11,702 | ||||||
| Earnings before provision for taxes on income percent to sales | 26.50% | 24.30% | 12.00% | 24.70% | ||||||
| Provision for taxes on income (Note 5) | $ 1,618 | $ 1,026 | $ 949 | $ 1,739 | ||||||
| Provision for taxes on income percent to sales | 6.40% | 4.30% | 1.90% | 3.70% | ||||||
| Net earnings | $ 5,144 | $ 4,814 | $ 5,076 | $ 9,963 | ||||||
| Net earnings percent to sales | 20.10% | 20.00% | 10.10% | 21.00% | ||||||
| NET EARNINGS PER SHARE | ||||||||||
| Basic (per share) | $ 1.98 | $ 1.83 | $ 1.95 | $ 3.79 | ||||||
| Diluted (per share) | $ 1.96 | $ 1.80 | $ 1.93 | $ 3.73 | ||||||
| AVG. SHARES OUTSTANDING | ||||||||||
| Basic (shares) | 2,598.4 | 2,629.6 | 2,601.9 | 2,629.4 | ||||||
| Diluted (shares) | 2,625.7 | 2,667.9 | 2,630.7 | 2,669.2 | ||||||
| ||||||||||
JNJ Balance Sheet
2023-07-02Consolidated Balance Sheets - USD ($) $ in Millions | Jul. 02, 2023 | Jan. 01, 2023 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents (Note 4) | $ 21,183 | $ 14,127 |
| Marketable securities | 7,322 | 9,392 |
| Accounts receivable, trade, less allowances $205 (2022, $203) | 16,777 | 16,160 |
| Inventories (Note 2) | 12,888 | 12,483 |
| Prepaid expenses and other | 2,397 | 3,132 |
| Total current assets | 60,567 | 55,294 |
| Property, plant and equipment at cost | 51,218 | 49,253 |
| Less: accumulated depreciation | (30,642) | (29,450) |
| Property, plant and equipment, net | 20,576 | 19,803 |
| Intangible assets, net (Note 3) | 46,246 | 48,325 |
| Goodwill (Note 3) | 45,440 | 45,231 |
| Deferred taxes on income (Note 5) | 8,779 | 9,123 |
| Other assets | 10,078 | 9,602 |
| Total assets | 191,686 | 187,378 |
| Current liabilities: | ||
| Loans and notes payable | 11,701 | 12,771 |
| Accounts payable | 10,443 | 11,703 |
| Accrued liabilities | 10,605 | 11,456 |
| Accrued rebates, returns and promotions | 15,672 | 14,417 |
| Accrued compensation and employee related obligations | 3,062 | 3,328 |
| Accrued taxes on income (Note 5) | 2,687 | 2,127 |
| Total current liabilities | 54,170 | 55,802 |
| Long-term debt (Note 4) | 33,901 | 26,888 |
| Deferred taxes on income (Note 5) | 3,627 | 6,374 |
| Employee related obligations (Note 6) | 6,461 | 6,767 |
| Long-term taxes payable (Note 5) | 2,536 | 4,306 |
| Other liabilities | 14,582 | 10,437 |
| Total liabilities | 115,277 | 110,574 |
| Commitments and Contingencies (Note 11) | ||
| Shareholders’ equity: | ||
| Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120 | 3,120 |
| Accumulated other comprehensive income (loss) (Note 7) | (13,135) | (12,967) |
| Retained earnings and Additional paid-in capital | 129,381 | 128,345 |
| Less: common stock held in treasury, at cost (521,700,000 and 506,246,000 shares) | 44,217 | 41,694 |
| Stockholders' Equity Attributable to Parent | 75,149 | 76,804 |
| Total Johnson & Johnson shareholders’ equity | 76,409 | 76,804 |
| Stockholders' Equity Attributable to Noncontrolling Interest | 1,260 | 0 |
| Total liabilities and shareholders’ equity | $ 191,686 | $ 187,378 |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.